Your email has been successfully added to our mailing list.

×
0.00106403559682723 0.000193461017604914 0.00193461017604942 -0.0014509576320372 0.00118011220739021 0.00309537628167918 0.0202166763397174 0.0344360611336816
Stock impact report

Oppenheimer Reaffirms Outlook on CRISPR Therapeutics (CRSP) After Encouraging Q3 Earnings Performance [Yahoo! Finance]

CRISPR Therapeutics AG - Common Shares (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time
Company Research Source: Yahoo! Finance
CRISPR Therapeutics AG (NASDAQ: CRSP ) ranks among the . Following the company's third-quarter financial results, Oppenheimer reaffirmed its Outperform rating and $95 price target for CRISPR Therapeutics AG (NASDAQ:CRSP) on November 11. CRISPR Therapeutics AG (NASDAQ:CRSP) reported a lower-than-anticipated loss of $1.17 per share against the expected $1.26 per share, largely due to reduced R&D spending of $59 million compared to the expected $88 million. Show less Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CRSP alerts
Opt-in for
CRSP alerts

from News Quantified
Opt-in for
CRSP alerts

from News Quantified